XORTX THERAPEUTICS INC

XRTXNASDAQ

Earnings Aug 13US Equity

$879.94▲ $1.50 (+0.17%)

Simulated price

1h—

24h▲ 0.2%

7d▲ 41406.6%

14d▲ 43034.3%

30d▲ 43034.3%

1y▲ 20040.5%

🏦Market Cap

$312.54B

Large Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

21.0%

Moderate

💵FCF Margin

0.1%

Thin

⚖️P/S Ratio

0.0x

Cheap

Otter Score

Weak

Trading Snapshot

Day Range: $875.25 – $885.66
52-Week Range: $2.42 – $9.85
Volume: $3.75B
Avg Volume: $2.55B
Shares Outstanding: 1.8M
Next Earnings: Oct 27, 2026

Fundamentals Snapshot

Annual Revenue: $42.81B
Last Q Revenue: $10.88B
P/E Ratio: —
P/S Ratio: 0.0x
EPS (TTM): $-2.65
Dividend Yield: —

Why Investors Own XRTX

✓High-growth profile — revenue up +51.6% YoY with expanding US Equity exposure.
✓Healthy economics — 79% gross margin and 15% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$42.81B▲ +44.4% YoY

Gross Margin (TTM)

78.5%▲ +0.7% YoY

Operating Income (TTM)

$10.92B▲ +44.4% YoY

Free Cash Flow (TTM)

$6.46B▲ +44.4% YoY

About XORTX THERAPEUTICS INC

XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to advancing and bringing to market medical treatments targeting a range of conditions, including chronic kidney ailments, diabetes, insulin resistance, metabolic syndrome, diabetic nephropathy, and various infections. Their pipeline includes XRx-008, a late-stage clinical program designed to address autosomal dominant polycystic kidney disease (ADPKD). Another key candidate is XRx-101, an agent aimed at reducing uric acid levels in COVID-19 patients, with the goal of mitigating acute kidney injury and related complications. Furthermore, they are developing XRx-221, a series of xanthine oxidase inhibitors intended for the management of diabetic nephropathy. XORTX also collaborates with the Icahn School of Medicine on research investigating acute kidney injury and hyperuricemia among hospitalized COVID-19 patients. The company's operations are headquartered in Vancouver, Canada.

🦦